A Longitudinal Study Examining Changes in Plasma Atherogenic Index and Its Association with Cardiometabolic Multimorbidity in Older Adults - Scorecard - MDSpire
Advertisement
A Longitudinal Study Examining Changes in Plasma Atherogenic Index and Its Association with Cardiometabolic Multimorbidity in Older Adults
Clinical Scorecard: A Longitudinal Study Examining Changes in Plasma Atherogenic Index and Its Association with Cardiometabolic Multimorbidity in Older Adults
At a Glance
Category
Detail
Condition
Cardiometabolic Multimorbidity (CMM)
Key Mechanisms
Association between Atherogenic Index of Plasma (AIP) and cardiovascular disease risk.
Target Population
Chinese middle-aged and elderly populations aged ≥ 45 years.
Care Setting
Community-based longitudinal study.
Key Highlights
CMM defined as coexistence of stroke, diabetes, and heart disease.
AIP is a significant predictor of cardiovascular events and mortality.
Longitudinal changes in AIP may better predict CMM risk than single measurements.
Study utilizes data from the China Health and Retirement Longitudinal Study (CHARLS).
CMM assessment based on standardized diagnostic criteria.
Guideline-Based Recommendations
Diagnosis
Assess CMM through standardized questions regarding diabetes, heart disease, and stroke.
Management
Implement early intervention measures for high-risk populations based on AIP levels.
Monitoring & Follow-up
Regularly monitor AIP levels to assess cardiovascular risk and CMM progression.
Risks
Increased risk of CMM associated with higher baseline AIP levels.
Patient & Prescribing Data
Older adults aged ≥ 45 years with potential cardiometabolic disorders.
Focus on controlling AIP levels to mitigate CMM risk.
Clinical Best Practices
Utilize longitudinal data to assess changes in AIP for better risk prediction.
Incorporate lifestyle modifications and medical management for diabetes, hypertension, and dyslipidemia.
